JP2017536353A - がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー - Google Patents
がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー Download PDFInfo
- Publication number
- JP2017536353A JP2017536353A JP2017523907A JP2017523907A JP2017536353A JP 2017536353 A JP2017536353 A JP 2017536353A JP 2017523907 A JP2017523907 A JP 2017523907A JP 2017523907 A JP2017523907 A JP 2017523907A JP 2017536353 A JP2017536353 A JP 2017536353A
- Authority
- JP
- Japan
- Prior art keywords
- raf
- cancer
- dapk
- sorafenib
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 70
- 201000011510 cancer Diseases 0.000 title claims abstract description 54
- 239000000090 biomarker Substances 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 238000007877 drug screening Methods 0.000 title claims abstract description 7
- 238000011282 treatment Methods 0.000 title abstract description 25
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims abstract description 79
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims abstract description 78
- 229960003787 sorafenib Drugs 0.000 claims abstract description 78
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 claims abstract description 16
- 230000010261 cell growth Effects 0.000 claims abstract description 16
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 13
- LMXYVLFTZRPNRV-KMKOMSMNSA-N (3z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1h-indol-2-one Chemical compound C1=C(Br)C(O)=C(Br)C=C1\C=C/1C2=CC(I)=CC=C2NC\1=O LMXYVLFTZRPNRV-KMKOMSMNSA-N 0.000 claims abstract description 7
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 claims abstract 8
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 claims abstract 8
- 210000004027 cell Anatomy 0.000 claims description 111
- 239000003814 drug Substances 0.000 claims description 60
- 229940079593 drug Drugs 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 35
- 230000026731 phosphorylation Effects 0.000 claims description 33
- 238000006366 phosphorylation reaction Methods 0.000 claims description 33
- 230000005764 inhibitory process Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 11
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 claims description 9
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 claims description 9
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 claims description 9
- 101150037250 Zhx2 gene Proteins 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 238000001647 drug administration Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 abstract description 65
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract description 9
- 206010038389 Renal cancer Diseases 0.000 abstract description 9
- 201000010982 kidney cancer Diseases 0.000 abstract description 9
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 9
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 abstract description 8
- 230000001394 metastastic effect Effects 0.000 abstract description 7
- 230000019491 signal transduction Effects 0.000 abstract description 6
- 238000010171 animal model Methods 0.000 abstract description 3
- 239000000890 drug combination Substances 0.000 abstract 1
- 238000010874 in vitro model Methods 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 102000005721 Death-Associated Protein Kinases Human genes 0.000 description 67
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 description 67
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 52
- 102100020870 La-related protein 6 Human genes 0.000 description 25
- 108050008265 La-related protein 6 Proteins 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 19
- 230000009036 growth inhibition Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000017074 necrotic cell death Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000030609 dephosphorylation Effects 0.000 description 7
- 238000006209 dephosphorylation reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 6
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 4
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 4
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 102220485636 Mitogen-activated protein kinase 15_K42A_mutation Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229930008399 cantharidic acid Natural products 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- ZZDBMDNRQQDSKG-UHFFFAOYSA-N methyl 5-bromo-1-benzofuran-2-carboxylate Chemical compound BrC1=CC=C2OC(C(=O)OC)=CC2=C1 ZZDBMDNRQQDSKG-UHFFFAOYSA-N 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000092 prognostic biomarker Substances 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 3
- 238000003210 sulforhodamine B staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009848 hypophosphorylation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006892 negative regulation of dephosphorylation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (17)
- ソラフェニブ及び3−(3,5−ジブロモ−4−ヒドロキシ−ベンジリデン)−5−ヨード−1,3−ジヒドロ−インドール−2−オンを含む、がんを治療するための医薬組成物。
- 前記組成物が、別々に、同時に、又は逐次的に投与される、請求項1に記載の医薬組成物。
- 前記がんが、腎細胞がん、前立腺がん、乳がん、肺がん、子宮頸がん、口腔がん、神経膠腫、尿路上皮細胞がん、又は黒色腫である、請求項1に記載の医薬組成物。
- 薬学的に許容される化合物の塩又は媒体をさらに含む、請求項1に記載の医薬組成物。
- 前記媒体が、賦形剤、希釈剤、増粘剤、充填剤、結合剤、崩壊剤、潤滑剤、油又は非油剤、界面活性剤、懸濁剤、ゲル化剤、アジュバント、防腐剤、酸化防止剤、安定剤、及び着色剤からなる群から選択される、請求項4に記載の医薬組成物。
- 前記医薬組成物が、経口投与、浸漬、注射、局所適用、又はパッチ投与によって投与される、請求項1に記載の医薬組成物。
- 前記3−(3,5−ジブロモ−4−ヒドロキシ−ベンジリデン)−5−ヨード−1,3−ジヒドロ−インドール−2−オンが、配列番号1の配列を有するc−Rafタンパク質に結合するとc−Rafタンパク質の立体配座を変化させ、c−Rafタンパク質を前記c−Raf/DAPKタンパク質複合体から解離させるために、前記ソラフェニブの前記c−Rafタンパク質への結合親和性を増加させる、請求項1に記載の医薬組成物。
- タンパク質複合体を解離する化合物であって、前記タンパク質複合体がc−Raf/DAPKタンパク質複合体であり、前記c−Rafタンパク質が配列番号1の配列を有し、前記DAPKタンパク質が配列番号2の配列を有する、前記タンパク質複合体を解離するための医薬の製造における前記化合物の使用。
- 前記化合物がソラフェニブ及び3−(3,5−ジブロモ−4−ヒドロキシ−ベンジリデン)−5−ヨード−1,3−ジヒドロ−インドール−2−オンである、請求項8に記載の使用。
- 検体を提供する工程と、
薬物の投与前に前記検体中のバイオマーカーのリン酸化レベルを検出する工程と、
前記バイオマーカーの前記リン酸化レベルが、前記薬物投与後の細胞増殖阻害率と正の相関を有する場合に、前記薬物が候補薬物であると判定する工程とを含み、
前記バイオマーカーは、配列番号1の配列を有するc−Rafタンパク質及び配列番号2の配列を有するDAPKタンパク質の少なくとも1つである、in vivoバイオマーカーを用いた薬物スクリーニング方法。 - 前記c−Rafタンパク質の前記セリン338(Ser338)アミノ酸残基がリン酸化され、前記DAPKタンパク質の前記セリン308(Ser308)アミノ酸残基がリン酸化される、請求項10に記載の方法。
- 前記検体が、手術後に収集された分離がん組織、腹水、血液、尿、糞便、喀痰、粘膜細胞、胃液又は胆汁がんである、請求項10に記載の方法。
- 前記候補薬物が、ソラフェニブ及び3−(3,5−ジブロモ−4−ヒドロキシ−ベンジリデン)−5−ヨード−1,3−ジヒドロ−インドール−2−オンである、請求項10に記載の方法。
- バイオマーカーが、配列番号1の配列を有するc−Rafタンパク質及び配列番号2の配列を有するDAPKタンパク質である、候補薬物のスクリーニングにおける前記バイオマーカーの使用。
- c−Rafタンパク質の前記セリン338(Ser338)アミノ酸残基がリン酸化され、DAPKタンパク質の前記セリン308(Ser308)アミノ酸残基がリン酸化される、請求項14に記載の使用。
- 前記候補薬物が、ソラフェニブ及び3−(3,5−ジブロモ−4−ヒドロキシ−ベンジリデン)−5−ヨード−1,3−ジヒドロ−インドール−2−オンを含む、請求項15に記載の使用。
- 薬物の投与前に前記バイオマーカーのリン酸化レベルを検出する工程と、
前記バイオマーカーの前記リン酸化レベルが、前記薬物投与後の細胞増殖阻害率と正の相関関係を有する場合に、前記薬物が候補薬物であると判定する工程とをさらに含む、請求項15に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/091712 WO2016078044A1 (zh) | 2014-11-19 | 2014-11-19 | 用于治疗癌症的药物组合物以及筛选药物的生物标记 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017536353A true JP2017536353A (ja) | 2017-12-07 |
JP6437649B2 JP6437649B2 (ja) | 2018-12-12 |
Family
ID=56013078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017523907A Active JP6437649B2 (ja) | 2014-11-19 | 2014-11-19 | がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3222276B1 (ja) |
JP (1) | JP6437649B2 (ja) |
CN (1) | CN107427492B (ja) |
AU (1) | AU2014411846B2 (ja) |
ES (1) | ES2880835T3 (ja) |
WO (1) | WO2016078044A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021533117A (ja) * | 2018-08-07 | 2021-12-02 | メタゴン バイオテック インク.Metagone Biotech Inc. | 3−(3,5−ジブロモ−4−ヒドロキシベンジリデン)−5−ヨード−1,3−ジヒドロインドール−2−オンのアンモニウム塩及びその使用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536632A (ja) * | 2006-05-11 | 2009-10-15 | ノバルティス アクチエンゲゼルシャフト | 医薬組合せ剤 |
JP2010535233A (ja) * | 2007-07-30 | 2010-11-18 | アルディア バイオサイエンス,インク. | Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用 |
US20110243957A1 (en) * | 2008-09-24 | 2011-10-06 | University Of South Florida | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation |
JP2013538856A (ja) * | 2010-10-01 | 2013-10-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013518909A (ja) * | 2010-02-08 | 2013-05-23 | キナゲン,インク. | アロステリックキナーゼ阻害が関係する治療方法および組成物 |
US20130266636A1 (en) * | 2010-08-12 | 2013-10-10 | The Regents Of The University Of California | Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition |
WO2012040527A2 (en) * | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
-
2014
- 2014-11-19 JP JP2017523907A patent/JP6437649B2/ja active Active
- 2014-11-19 WO PCT/CN2014/091712 patent/WO2016078044A1/zh active Application Filing
- 2014-11-19 EP EP14906443.8A patent/EP3222276B1/en active Active
- 2014-11-19 CN CN201480082879.7A patent/CN107427492B/zh active Active
- 2014-11-19 AU AU2014411846A patent/AU2014411846B2/en active Active
- 2014-11-19 ES ES14906443T patent/ES2880835T3/es active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536632A (ja) * | 2006-05-11 | 2009-10-15 | ノバルティス アクチエンゲゼルシャフト | 医薬組合せ剤 |
JP2010535233A (ja) * | 2007-07-30 | 2010-11-18 | アルディア バイオサイエンス,インク. | Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用 |
US20110243957A1 (en) * | 2008-09-24 | 2011-10-06 | University Of South Florida | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation |
JP2013538856A (ja) * | 2010-10-01 | 2013-10-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Non-Patent Citations (2)
Title |
---|
CLIN CANCER RES, vol. 15, JPN6018007355, 2009, pages 5704 - 5713, ISSN: 0003898563 * |
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, vol. 9, JPN6018007356, 2010, pages 120 - 127, ISSN: 0003898564 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021533117A (ja) * | 2018-08-07 | 2021-12-02 | メタゴン バイオテック インク.Metagone Biotech Inc. | 3−(3,5−ジブロモ−4−ヒドロキシベンジリデン)−5−ヨード−1,3−ジヒドロインドール−2−オンのアンモニウム塩及びその使用 |
JP7201273B2 (ja) | 2018-08-07 | 2023-01-10 | メタゴン バイオテック インク. | 3-(3,5-ジブロモ-4-ヒドロキシベンジリデン)-5-ヨード-1,3-ジヒドロインドール-2-オンのアンモニウム塩及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2014411846B2 (en) | 2018-02-22 |
WO2016078044A1 (zh) | 2016-05-26 |
EP3222276B1 (en) | 2021-04-07 |
JP6437649B2 (ja) | 2018-12-12 |
AU2014411846A1 (en) | 2017-04-27 |
CN107427492A (zh) | 2017-12-01 |
ES2880835T3 (es) | 2021-11-25 |
EP3222276A4 (en) | 2018-10-10 |
EP3222276A1 (en) | 2017-09-27 |
CN107427492B (zh) | 2021-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tu et al. | Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3 | |
Bubici et al. | JNK signalling in cancer: in need of new, smarter therapeutic targets | |
Nakasone et al. | Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance | |
Germani et al. | Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A | |
CN107106580B (zh) | 治疗癌症干细胞的组合物 | |
Lee et al. | Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1 | |
Liao et al. | CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions | |
Lee et al. | Tissue transglutaminase activates cancer-associated fibroblasts and contributes to gemcitabine resistance in pancreatic cancer | |
Karim et al. | Prom1 function in development, intestinal inflammation, and intestinal tumorigenesis | |
Sha et al. | Antitumor properties of Salvianolic acid B against triple-negative and hormone receptor-positive breast cancer cells via ceramide-mediated apoptosis | |
US9782393B2 (en) | Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening | |
Jiang et al. | Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation | |
Sun et al. | Anoctamin 1 controls bone resorption by coupling Cl− Channel activation with RANKL-RANK signaling transduction | |
Shen et al. | Sinoporphyrin sodium-mediated sonodynamic therapy inhibits RIP3 expression and induces apoptosis in the H446 small cell lung cancer cell line | |
Fang et al. | Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts | |
Yang et al. | Metformin enhances the effect of regorafenib and inhibits recurrence and metastasis of hepatic carcinoma after liver resection via regulating expression of hypoxia inducible factors 2α (HIF-2α) and 30 kDa HIV tat-interacting protein (TIP30) | |
Lin et al. | Inhibition of transient receptor potential melastain 7 enhances apoptosis induced by TRAIL in PC-3 cells | |
Tong et al. | A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma | |
Tseng et al. | Caffeic acid phenethyl ester suppresses EGFR/FAK/Akt signaling, migration, and tumor growth of prostate cancer cells | |
Jin et al. | Effect of sufentanil on the viability and apoptosis of cervical cancer cells via the inactivation of PI3K/AKT/mTOR signaling pathway | |
Tada et al. | The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma | |
JP6437649B2 (ja) | がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー | |
Zhang et al. | Chenodeoxycholic acid enhances the effect of sorafenib in inhibiting HepG2 cell growth through EGFR/Stat3 pathway | |
Cherradi et al. | Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells | |
Liu et al. | Implication of myeloid differentiation factor 88 inhibitor TJ‐M2010‐5 for therapeutic intervention of hepatocellular carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170628 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181016 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6437649 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |